Sothic Bioscience has successfully completed preclinical studies for their lead therapy and is preparing for Phase 1 clinical trials. The company has also secured partnerships with key research institutions and patient advocacy groups to advance their pipeline of genetic therapies.
Organizations Involved
SOSV, XYZ Ventures, RareGenetics Foundation
Founders
Emily Chen, Michael Patel
Company Description
Sothic Bioscience is a biotech company specializing in developing innovative therapies for rare genetic disorders. Their focus is on leveraging advanced gene editing technologies to address unmet medical needs in the rare disease space. By targeting specific genetic mutations, Sothic Bioscience aims to provide personalized treatments that can significantly improve the quality of life for patients with these conditions.